Literature DB >> 25827592

In vitro effects of binuclear (η (6)-p-cymene)ruthenium(II) complex containing bridging bis(nicotinate)-polyethylene glycol ester ligand on differentiation pathways of murine Th lymphocytes activated by T cell mitogen.

Miljana Momcilovic1, Thomas Eichhorn, Jana Blazevski, Harry Schmidt, Goran N Kaluđerović, Stanislava Stosic-Grujicic.   

Abstract

T cell differentiation into distinct T helper (Th) subpopulations is crucial in governing acquired immune responses as well as some inflammatory and autoimmune disorders. This study investigated potential of the novel neutral binuclear ruthenium(II) complexes 1-8 with general formula [{RuCl2(η(6)-p-cym)}2μ-(N(∩)N)] (N(∩)N = bis(nicotinate)- and bis(iso-nicotinate)-polyethylene glycol esters; (3-py)COO(CH2CH2O) n CO(3-py) and (4-py)COO(CH2CH2O) n CO(4-py); n = 1-4), as well as [RuCl2(η(6)-p-cym)(nic)] (R1, nic = nicotinate) and [RuCl2(η(6)-p-cym)(inic)] (R2, inic = isonicotinate) as an immunomodulatory agents capable to direct Th cell differentiation. From all investigated complexes, [{RuCl2(η(6)-p-cym)}2μ-{(3-py)COO(CH2CH2O)4CO(3-py)}] (4) was selected for further study because it did not affect splenocyte viability (in concentration up to 50 μM), but significantly reduced secretion of representative Th1 cytokine, IFN-γ induced by T cell mitogen. Besides IFN-γ, 4 inhibited dose dependently expression and production of representative Th17 cytokine, IL-17, in these cells. Otherwise, the production of anti-inflammatory cytokines IL-4 and IL-10 was upregulated. Also, 4 significantly increased CD4(+)CD25(+)FoxP3(+) Treg cell frequency in the activated splenocytes. Moreover, ConA-induced expression of Th1 transcription factors, T-bet and STAT1, as well as of Th17-related protein STAT3 was attenuated upon exposure to 4, while the expression of Th2-related transcription factor GATA3 remained stable. In conclusion, ruthenium(II) complex 4 modulates immune system cell functions in vitro by inhibiting T cell differentiation towards pathogenic Th1/Th17 phenotype and inducing a regulatory phenotype characterized by IL-10 and IL-4 production, which may provide novel therapeutic opportunities for immune-inflammatory and/or autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25827592     DOI: 10.1007/s00775-015-1242-x

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  45 in total

1.  Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds.

Authors:  Alexey A Nazarov; Julie Risse; Wee Han Ang; Frederic Schmitt; Olivier Zava; Albert Ruggi; Michael Groessl; Rosario Scopelitti; Lucienne Juillerat-Jeanneret; Christian G Hartinger; Paul J Dyson
Journal:  Inorg Chem       Date:  2012-03-06       Impact factor: 5.165

2.  Macrophage migration inhibitory factor deficiency protects pancreatic islets from palmitic acid-induced apoptosis.

Authors:  Tamara Saksida; Stanislava Stosic-Grujicic; Gordana Timotijevic; Stellan Sandler; Ivana Stojanovic
Journal:  Immunol Cell Biol       Date:  2011-11-08       Impact factor: 5.126

Review 3.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

4.  Synthesis, characterization, DNA interaction, antioxidant and anticancer activity studies of ruthenium(II) polypyridyl complexes.

Authors:  Guang-Bin Jiang; Yang-Yin Xie; Gan-Jian Lin; Hong-Liang Huang; Zhen-Hua Liang; Yun-Jun Liu
Journal:  J Photochem Photobiol B       Date:  2013-10-15       Impact factor: 6.252

Review 5.  Ruthenium-based chemotherapeutics: are they ready for prime time?

Authors:  Emmanuel S Antonarakis; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-06       Impact factor: 3.333

Review 6.  Drug control of solid tumour metastases: a critical view.

Authors:  G Sava; A Bergamo
Journal:  Anticancer Res       Date:  1999 Mar-Apr       Impact factor: 2.480

7.  The ruthenium complex cis-(Dichloro)Tetraammineruthenium(III) chloride presents immune stimulatory activity on human peripheral blood mononuclear cells.

Authors:  Elisângela de Paula Silveira-Lacerda; Cesar Augusto Sam Tiago Vilanova-Costa; Flávia de Castro Pereira; Amélia Hamaguchi; Luiz Alfredo Pavanin; Luiz Ricardo Goulart; Maria Inês Homsi-Brandenburgo; Andreimar Martins Soares; Wagner Batista dos Santos; Auro Nomizo
Journal:  Biol Trace Elem Res       Date:  2009-07-10       Impact factor: 3.738

8.  Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.

Authors:  Timothy J Harris; Joseph F Grosso; Hung-Rong Yen; Hong Xin; Marcin Kortylewski; Emilia Albesiano; Edward L Hipkiss; Derese Getnet; Monica V Goldberg; Charles H Maris; Franck Housseau; Hua Yu; Drew M Pardoll; Charles G Drake
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

Review 9.  Th17 cells: from precursors to players in inflammation and infection.

Authors:  Amit Awasthi; Vijay K Kuchroo
Journal:  Int Immunol       Date:  2009-03-04       Impact factor: 4.823

10.  Chlorido-containing ruthenium(II) and iridium(III) complexes as antimicrobial agents.

Authors:  Mallesh Pandrala; Fangfei Li; Marshall Feterl; Yanyan Mulyana; Jeffrey M Warner; Lynne Wallace; F Richard Keene; J Grant Collins
Journal:  Dalton Trans       Date:  2013-04-07       Impact factor: 4.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.